Metabolic Consequences of Folate-Induced Reduction of Hyperhomocysteinemia in Uremia
|
|
- Lee Bell
- 6 years ago
- Views:
Transcription
1 Metabolic Consequences of Folate-Induced Reduction of Hyperhomocysteinemia in Uremia ALSSANDRA F. PRNA,*f DIGO INGROSSO,* NATAL G. D SANTO,t PATRIZIA GALLTTI,* MASSIMILIANO BRUNON,* and VINCNZO ZAPPIA*I *Instjtute of Biochemistry of Macromolecules, Division of Nephrologv/Department of Pediatrics, Sc/tool of Medicine and Surgery, Second University of Naples, Naples, Italy; tlnstitute of Food Sciences and Technology, Avellino, Italy. Abstract. Plasma homocysteine, a well-recognized risk factor for cardiovascular disease, is elevated in uremic patients on hemodialysis. The authors have recently demonstrated that one consequence is the reduction in red cell membrane protein methylation levels, caused by a rise of intracellular adenosylhomocysteine, a potent inhibitor of methyltransferases. Protein methylation is involved in a repair mechanism of damaged membrane proteins, and an impairment in methylation leads to the accumulation of altered proteins. Therapy with folates, cofactors in the transformation of homocysteine to methionine, is effective in lowering plasma homocysteine. This article details a study on the metabolic effects of oral methyltetrahydrofolate, the active form of folic acid, on 14 uremic hemodialysis patients. Two months of therapy led to a significant reduction of plasma homocysteine levels, with a proportional response to pre-folate levels. In five of 1 3 patients with homocysteine levels above 2 pm, plasma homocysteine level was reduced to less than I 5 M. After treatment, levels of adenosylmethionine, the methyl donor in transmethylations. had significantly increased; levels of adenosylhomocysteine had increased to a smaller extent. Therefore, the ratio between the two compounds, an excellent indicator of the presence and the degree of methybation inhibition, was significantly ameliorated. Methionine plasma levels increased after treatment in all patients and were correlated with posttreatment adenosybmethionine levels. It was concluded that treatment with methyltetrahydrofolate brings the plasma homocysteine concentration back to an acceptable level, and the metabolic consequences are in the direction of an increase in the normal flow of transmethybations, as monitored by an increase in the ladenosylmethionine}/[adenosylhomocysteine] ratio. (J Am Soc Nephrol 8: , 1997) Recently, homocysteine plasma level has been widely recognized as an independent predictor of an increase in cardiovascular disease accidents (1-5). ven a modest elevation is significantly correlated with an increase in the risk of occurrence of myocardial infarction, stroke, and peripheral artery and deep vein thrombosis (1-5). nd-stage renal disease patients, whose death rate due to cardiovascular accidents is 4% (6), show a significant elevation in homocysteine plasma levels (7-1 1) to be ascribed to a reduction in the metabolic functions of damaged kidneys. rather than to a diminished excretion of this amino acid (12-14). Homocysteinemia increases to levels that in hemodialysis patients are well above the 95% percentile of a healthy reference population; that is, 1 5 p.m (15,16). In erythrocytes from chronic renal failure and hemodialysis patients, we have previously demonstrated that an elevation in plasma homocysteine level beads to an increased level of its precursor, adenosylhomocysteine ( 1 7), a potent natural inhibitor of all adenosylmethionine-dependent transmethylation re- Received March Accepted May 14, Correspondence to Dr. Diego Ingrosso, Istituto di Biochimica delle Macromolecole, Facolt#{224} di Medicina e Chirurgia, Seconda Universit#{224}degli Studi di Napoli, via Costantinopoli 16, 8138 Napoli. Italy / $3./ Journal of the American Society of Nephrology Copyright 1997 by the American Society of Nephrology actions ( 18-22). According to this notion. it has been shown that an increased adenosylhomocysteine level, in uremic patients, significantly inhibits the adenosylmethionine-dependent repair of molecular fatigue damage in membrane proteins (17,23-2S). Based on the mechanism of the thioether inhibitory effect upon transmethylation reactions, it has been shown that the [adenosylmethionine]/[adenosylhomocystei ne] ratio can be used as a key metabolic parameter to evaluate the degree of such inhibition (17-23). It has been shown, in fact. that the reduction of this ratio reflects the chronic derangement of protein repair in uremia (17,25). Folic acid, and its active circulating derivative 5-methyltetrahydrofolate (MTHF), functions as the one-carbon donor in the remethylation pathway from homocysteine to methionine. the in vito adenosylmethionine precursor (26,27). Folate therapy is known to reduce homocysteine plasma levels in hyperhomocysteinemic patients (except in cases of homozygous cystathionine -synthase-deficient homocystinunia, in which vitamin B6 is usually sufficient), such as patients with increased risk of cardiovascular accidents, including those affected by chronic renal failure (28-3). We have therefore started this study to assess the effects of MTHF on the methionine-homocysteine cycle and to clarify whether a reduction in homocysteine plasma levels induced by MTHF administration affects the ladenosylmethioninel/lad-
2 19 Journal of the American Society of Nephrology enosylhomocysteine] ratio, which is the crucial indicator of the presence and degree of methylation inhibition (18-22). Materials and Methods Patients and Treatment Sixteen end-stage renal disease patients were selected, provided that they were not affected by systemic diseases such as lupus erythematosus. arterial hypertension antecedent to renal failure, diabetes mellitus. cardiac disease, etc. Patients were being treated by regular bicarbonate hemodialysis treatment. thrice weekly, using hollow-fiber no-reuse dialyzers. Kt/V was routinely checked with monthly intervals and was always above 1.5 during the study and in the previous 6 mo. Patients, for a washout period of 2 mo, did not receive any group B vitamins or phosphodiesterase inhibitors (31). MTHF (Prefolic, Knoll. Germany) was administered for 2 mo at a dose of 15 mg/day per os. Compliance with treatment was assessed by pill count. A report of symptoms after the start of therapy was requested from each patient. Two patients dropped out from the study: one left to undergo a kidney transplant, and the other died of respiratory complications. Blood was drawn by venipuncture while the patient was in a fasting state at the start and at the end of the study immediately before the dialysis session by using ethylenediaminetetraacetate ( 1 mg/ml of blood). Whole blood was immediately centrifuged to separate plasma from cells. Plasma aliquots were stored at -8#{176}Cbefore homocysteine determination. Packed red cells were obtained according to the procedure of Perna ci al. ( I 7). Routine blood biochemical tests (using the Hitachi 91 1 Automatic Analyzer. Hitachi. Tokyo, Japan) were performed before and after treatment. Plasma Ho,nocysteine Plasma homocysteine concentration was determined according to the method of Ubbink et al. (32), as modified by Perna et al. (33). Homocysteine represents total. protein-bound. and non-protein-bound homocysteine. In brief, the procedure involved a preliminary step of reduction and release from plasma proteins. using tni-n-butyl-phosphine in dimethylformamide. followed by precolumn derivatization with ammonium 7-fluorobenzo-2-oxa- I.3-diazole-4-sulphonate (SBD-F. a thiol-specific fluorogenic probe). The mobile phase was.1 M KH2PO4. ph containing 4% acetonitrile, with a flow rate of 2. mi/mm. Micromolar concentrations of homocysteine are referred to 1 liter of plasma. Detection conditions were optimized for homocysteine. Fluorescence intensities were measured with excitation at 385 nm and emission at 5 15 nm using a Shimadzu RF-535 fluorescence detector (Shimadzu Co.. Kyoto, Japan), equipped with a Shimadzu Chromatopac C-R6A data processor. Pre-folate and after-folate homocysteine level determinations were performed at the same time for each patient. Methionine Determination Plasma methionine was assayed according to the method of Jones et al. (34). In brief, plasma samples were deproteinized by perchloric acid precipitation and neutralized by KOH. The insoluble KCIO4 was removed by centrifugation. Pre-column derivatization was then performed by adding 15 jsl of o-phtalaldehyde solution (5 mg in I.5 ml methanol, plus 5 p1 -niercaptoethanol and 1.2 ml of a.4 mm potassium borate solution. ph 1.4) to 1 pj of each sample just before injection. A C- I 8 15 mm X 5 mm reverse-phase column was used (Supelco: Du Pont, Boston. MA). The mobile phase components used were the killowing: buffer A, 5 mm sodium phosphate/so mm sodium acetate, ph % tetrahydrofurane. and 2% methanol; buffer B. 65% methanol. 45% Milli-Q Millipore water. Buffer B increased from 1% to 1% in 35 mm, then S mm of isocratic elution at 1% buffer B followed. Reequilibration of the system to the initial conditions required S mm. The flow rate was 1.5 mllmin. The fluorometric detector was set at 335 nm excitation and 445 nm emission. Adenosylmethion me and Adenosylhomocysteine Determinations Adenosylmethionine and adenosylhomocysteine were determined chromatographically in red blood cells following the method modified by Perna et al. (17). Statistical Analyses Statistical analyses were performed using the paired a test. Linear regression analysis was done to assess the independent effects of the different variables (35). All calculations were performed using the software package StatWorks (Cricket Software. Philadelphia, PA), running on an Apple Macintosh IIfx (Cupertino. CA) personal computer. All results are presented as means ± SM. Results MTHF ffects on Homocvsteine Levels in Hemodialysis Patients The effect of 2 mo of treatment with MTHF are reported in Table 1, whereas data from individual patients are shown in Figure 1. The mean plasma homocysteine concentration decreased significantly after 2 mo of therapy. It can be noted that the majority of patients had levels above 2 M before MTHF treatment, and in five of these 13 patients there was a reduction to less than 15 p.m, which is considered an acceptable ( normative ) range (3). The higher the plasma homocysteine pretreatment levels were, the greater the decrease after therapy (coefficient of correlation r =.98, P = <.1). Table 1. Key patient characteristics before and after Parameter treatment with MTHF. Medium Before MTHF (n 14) After MTHF (ii = 14) Homocysteine (p.m) P ± ± 237b Methionine (M) P 3.78 ± ± 5.36c Urea(mg/dl) P 153.7± ± Creatinine (mg/dl) P 9.31 ± ±.69 AST (Un) P ± ± 1.78 ALT (U/I) P 8. ± ±.55 AdoMet (p.m) ± ± 658b AdoHcy (p.m) 2.68 ± ± 784d AdoMet/AdoHcy ± ± 737d a MTHF, 5-methyltetrahydrofolate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AdoMet, adenosylmethionine; AdoHcy, adenosylhomocysteine: P, plasma;, erythrocyte. hp <.3. C p <.6. d p < o.os.
3 Folates and Hyperhomocysteinemia in Uremia 19()l a) C a) (1) > C.) I Ce U) Ce enzymatic methylations is donated by adenosylmethionine. We measured methionine plasma levels in hemodialysis patients before and after MTHF treatment. We found that methionine levels significantly increased after treatment (Table 1). Methionine is, in turn, the in vivo precursor of the methyl donor adenosylmethionine (23.27). Red cell adenosylmethionine concentration increased significantly after 2 mo of therapy with MTHF in hemodialysis patients (Figure 3. panel A, and Table I). In our study, we found that the difference between pretreatment and posttreatment methionine levels significantly correbated with posttreatment adenosybmethionine levels (r =.76, P <.1). These results substantiate the interpretation that treatment of hemodialysis metabolism with folates leads to an improvement of homocysteine metabolism through the remethylation pathway, which ultimately leads to a significant increase of the intracellular pool of the methyl donor adenosylmethionine. The large majority of the adenosylmethionine formed is consumed in transmethylation reactions, yielding adenosylhomocysteine as the demethylated product (27). We measured the concentration of this thioether in red cells of hemodialysis patients before and after 2 mo of MTHF treatment. Adenosylhomocysteine concentration increased, but to a smaller extent with respect to adenosylmethionine (Figure 3, panel B, and Table I). The [adenosylmethionine]/[adenosylhomocysteinej ratio, a crucial indicator of the presence and degree of methylation inhibition, increased significantly after therapy (Table I ). These results prompted us to conclude that treatment with MTHF critically relieves transmethylation inhibition in hemodialysis patients. The mechanism consists in the facilitated removal of excess homocysteine, which induces an increase of the biosynthesis of the methyl donor adenosylmethionine. and, at the same time, favors the hydrolysis of adenosylhornocysteine, the common product of transmethylations. - #{182} Before MTHF After MTHF Figure 1. Plasma homocysteine concentration of individual patients before and after 2 mo of treatment with oral 5-methyltetrahydrofolate (MTHF). After 2 mo of treatment with MTHF, plasma homocysteine levels decreased in all 14 patients. In 13 patients with pretreatment levels above 2 M, homocysteine levels decreased to values less than 15,.M in five patients. valuation of the intermediates of Methionine- Homocysteine Cycle in Hemodialysis Patients The metabolism of methionine can be envisioned as a true metabolic cycle because the carbon backbone of this amino acid is sequentially converted to adenosybmethionine, then to adenosylhomocysteine, and finally to homocysteine (Figure 2). Methionine is the product of homocysteine metabolism through homocysteine remethylation. This reaction crucially depends on MTHF, which acts as the methyl donor (27). It is worth noting that this is the only methyl transfer reaction in which MTHF donates the methyl group, which in all other Biochemical and Clinical Parameters The main biochemical parameters-urea, creatinine, aspartate aminotransferase, alanine aminotransferase- of patients before and after therapy are reported in Table 1. There was no significant difference in these parameters after therapy with MTHF. Moreover, our patients did not report any side effects or particular complaints during folate administration, cornpared with the previous period. Compliance was excellent because the patients were closely followed and counseled in relation to the importance of strict adherence to therapy. Discussion In the work presented here, we demonstrate that lowering plasma homocysteine levels in hemodialysis patients by using MTHF, the methyl donor in homocysteine conversion to methionine, leads to a significant reduction of homocysteinemia and to an increase of the intracellular concentration of adenosylmethionine. adenosylhomocysteine, and their ratio. Plasma homocysteine levels are a recognized predictor of an individual s risk of cardiovascular complications. Investigated explanations of homocysteine toxicity are various. including
4 192 Journal of the American Society of Nephrology CYSTIN HOMOCYSTIN MTHF THF ADNOSYLHOMOCYSTIN MTHIONIN MTHYLATD MTHYL ACCPTORS MTHYL ACCPTORS ADNOSYLMTHIONIN Figure 2. The methionine-homocysteine cycle. Adenosylmethionine, enzymatically synthesized from methionine and ATP (step 1), is the common methyl donor for transmethylation reactions catalyzed by methyltransferases, which transfer the methyl groups to methyl acceptors; adenosylhomocysteine is the common demethylated product of these reactions, as well as the competitive inhibitor of adenosylmethioninedependent methyltransferases (step 2). Adenosylhomocysteine is hydrolyzed to adenosine and homocysteine in a reversible reaction catalyzed by adenosylhomocysteine hydrolase (step 3). Homocysteine is utilized for methionine resynthesis in a reaction catalyzed by methionine synthase (step 4). The methyl donor for this reaction is MTHF. Homocysteine is also metabolized through the side-pathway of transsulfuration (step 5). This process involves the sequential action of cystathionine--synthase and cystathioninase, beading to cysteine (23,26,27). 14 ri >1 6 U 4 V Before MTHF After MTHF Before MTHF After MTHF Figure 3. Adenosylmethionine (panel A) and adenosylhomocysteine (panel B) concentrations of individual patients before and after 2 mo of treatment with oral MTHF. Adenosylmethionine and adenosylhomocysteine concentrations were measured in the acid soluble fraction of erythrocyte cytosol by means of high-performance liquid chromatography ( 17). AdoMet, adenosylmethionine; AdoHcy, adenosylhomocysteine. stimulation of muscle cell proliferation; increased binding of dying of cardiovascular accidents (6). Their average plasma Lp(a) to fibnin. a significant prooxidative activity; and activa- homocysteine concentration is well above the top 5% of a tion of factor V of coagulation or of thrombomodulin expres- normal reference population, even if supplemented with twosion (36-4). to threefold physiologic doses of B vitamins (15,16). More- nd-stage renal disease patients have an increased risk of over, hemodialysis lowers plasma homocysteine levels only
5 Folates and Hyperhomocysteinemia in Uremia 193 partially (7,41). Thus uremia represents a suitable model to study the metabolic effects of hyperhomocysteinemia and its management. Our study was specifically undertaken to elucidate the mechanism of the effect of folate upon elevated homocysteinemia in end-stage renal disease. For this purpose we used MTHF, the readily available form of folate, as a direct precursor of the methyl moiety for methionine resynthesis from homocysteine. Before MTHF administration, a vitamin B washout period was performed in our study to obtain a baseline situation with high homocysteine levels, reflecting those present in standard hemodialysis patients, in whom either no folate supplementation or a low-dose supplementation is prescribed (7-1 1, 15,29,3,41-43). Diet was not modified, therefore the usual dietary folate intake was maintained. However, the washout period cannot be expected to induce an unusual state of folate deficiency because it has been described that after a three- (42) or four (29)-month washout period, blood folate concentrations were still significantly above the upper reference limit. This is consistent with the report that end-stage renal disease patients have folate plasma levels higher than those in a comparable population of healthy individuals (15). Nevertheless, folate levels are, in renal disease patients. inversely correlated with the degree of hyperhomocysteinemia (15). These data have been interpreted in the light of a relative resistance to folate in kidney failure (16,3). Although folate levels were not determined in our study, the mean (Table 1) or the median (45 M) homocysteine prefolate plasma levels compare with values obtained in hemodialysis patients (7-1 1,15,29,3,41,43), as well as other key parameters given in Table 1. We can conclude therefore that our patient population reflected a typical hemodialysis patient population. We have previously demonstrated that as a consequence of the increased plasma levels of homocysteine in uremic patients, a rise in the intracellular concentration of adenosylhomocysteine emerges (17). This thioether is the precursor of homocysteine and the natural inhibitor of all adenosylmethionine-dependent transmethylation reactions (1 8-22). The ratio [adenosylmethionine]/[adenosylhomocysteine] is the most reliable indicator of the normal flow of methyl groups transferred from the methyl donor to methyl acceptors within the cell (18-22). In this respect, we would like to quote,... it has become well established that modulation of adenosylmethionine/adenosylhomocysteine ratios can be utilized to probe for the involvement of methylation reactions in a variety of physiological systems since changes in this ratio brought about by pharmacological manipulations can be associated with striking biological effects (22). We previously found that the reduction of the [adenosylmethionine]/[adenosylhomocysteine] 1evels, measured by straightforward analytical procedures ( 17), is in good agreement with the degree of impairment of membrane protein repair (25). We have demonstrated that the rise of adenosylhomocysteine concentration in uremia, which is not paralleled by any rise of adenosylmethionine concentration, gives way to a significant reduction of the [adenosylmethionine]/[adenosylhomocysteine] ratio (17). The finding that a reduction of homocysteine plasma levels, as it is induced by the oral administration of MTHF for 2 mo to hemodialysis patients. is important with respect to the metabolic repercussions of MTHF administration, because MTHF is able to increase the [adenosylmethionine]/[adenosylhomocysteine] ratio to levels not significantly different from those detected in healthy individuals (17,33). In fact, the MTHFinduced increase in methionine is handled by the cell through an increase in adenosylmethionine, an ATP-dependent reaction (erythrocyte ATP concentration is normal, if not elevated in uremic cells, 44). Treatment with MTHF in hemodialysis patients increases the [adenosylmethionine]/[adenosylhomocysteine] ratio, indicating that the blockage in the normal flow of transmethylations is eased, if not dispelled, by treatment with MTHF. An increase in transmethylations should therefore induce a diminished accumulation of altered proteins. with the relevant consequences in terms of protein function. Our findings involve other considerations as well, because several crucial transmethylation-dependent processes, in addition to protein repair in cells different from erythrocytes. can be affected by a reduction in the [adenosylmethioninel/ladenosylhomocysteine] ratio (23). In conclusion, our findings clarify the mechanism and the metabolic consequences of the reduction of plasma homocysteine levels induced in hemodiabysis patients by the administration of pharmacological doses of folates. as advocated by concerns related to the increase in the cardiovascular risk associated with hyperhomocysteinemia. We conclude that the benefits are not only in the direction of reducing hyperhomocysteinemia. whose reflections on cardiovascular risk remain to be established, but also in preventing the metabolic alterations induced at a cellular level by the decreased fadenosylmethionine]/[adenosylhomocysteine] Acknowledgments ratio. This work was partially supported by grants from the Ministry of University and Scientific and Technological Research. from Targeted Project Prevention and Control of Disease Factors, and from the National Research Council to the Institute of Biocheniistry of Macromolecules and the Chair of Nephrology. References I. Clarke R, Daly L. Robinson K. Naughten. Cahalane S. Fowler B, Graham I: Hyperhomocysteinemia: An independent risk factor for vascular disease. N ngi J Med 324: Stampfer Mi, Malinow MR. Willett WC. Newcomer LM. Upson B. Ullmann D. Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268: Malinow MR. Nieto FJ, Szklo M, Chambless L, Bond G: Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: The atherosclerosis risk in communities study. Circulation 87: , Nygard. Vollset S. Refsum H, Stensvold I. Tverdal A. Nordrehaug J, Ueland PM. Kvale G: Total plasma homocysteine and cardiovascular risk profile: The Hordaland homocysteine study. JAMA 274: Robinson K, Mayer L, Miller DP, Green R, van Lente F. Gupta
6 194 Journal of the American Society of Nephrology A. Kottke-Marchant K. Savon SR. Selhub I. Nissen S. Kutner M. Topol l. Jacobsen DW: 1-lyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease. Circulation 92: I Parfrey PS: Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney I)is 21: 77-8, Wilcken DL. Gupta Vi. Reddy SG: Accumulation of sulfurcontaining amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. C/in Sci 58: , Chauveau P. Chadefaux B. Coud#{233}M. Aupetit J, Hannedouche T. Kamoun P. iungers P: Increased plasma homocysteine concentration in patients with chronic renal failure. Miner lectrolyte Metab 1992:18: Chauveau P. Chadefaux B, Coud#{232}M, Aupetit I. Hannedouche T, Kanioun P. iungers P: Hyperhomocysteinemia. a risk factor for atherosclerosis in chronic uremic patients. Kidney hit 43: S72- S77, Hultberg B. Andersson A, Sterner G: Plasma homocysteine in renal failure. C/in Nephrol 4: , 1993 I I. Bachmann J. Tepel M. Raidt H. Riezler R. Graefe U, Langer K, Zidek W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6: , I 995 I 2. Guttormsen AB, Svarstad, Ueland PM, Refsum H: limination of hoinocysteine from plasma in subjects with end stage renal failure. Jr J Med Sd 164: (S)8-(S)9, Bostom AG. Brosnan IT, Hall B, Nadeau MR. Selhub I: Homocysteine metabolism by the rat kidney in vivo. JrfMedSci 164: (S)2-(S) Bostom AG. Brosnan it. Hall B. Nadeau MR, Selhub I: Net uptake of plasma homocysteine by the rat kidney in vivo. Atheroselerosis 1 16: 59-62, 1995 I 5. Robinson K. Gupta A. Dennis V. Arheart D. Chaudhary D. Green R, Vigo P. Mayer L. Selhub I. Kutner M, iacobsen DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pinidoxine concentrations. Circulation 94: Dennis VW, Robinson K: Homocysteinemia and vascular disease in end stage renal disease. Kidney In! 5(57): I Perna AF. Ingrosso D. Zappia V. Galletti P. Capasso G, De Santo NG: nzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure: vidence for high levels of the natural inhibitor 5-adenosylhomocysteine. J Cliii Invest 9 1: , 1993 I 8. Zappia V. Zydek-Cwick CR, Schlenk F: The specificity of 5- adenosylmethionine derivatives in methyl transfer reactions. J Biol Cheni 244: Cantoni GL, Richards HH, Chiang PK: Inhibitors of 5-adenosylhomocysteine hydrolase and their role in the regulation of biological methylation. In: Transmethvlations. edited by Usdin. Borchard RT. Creveling CR. Amsterdam. lsevier/north Holland, 1979, pp Cantoni GL, Chiang PK: The role of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase in the control of biologic methylations. In: Natural Sulfur Compounds: Novel Biochemical and Structural Aspects. edited by Cavalbini D. Gaull G, Zappia V. New York. Plenum Press, 198, pp Barber JR. Clarke 5: Inhibition of protein carboxyb methylation by S-adenosyl-L-homocysteine in intact erythrocytes: Physiological consequences. J Biol Chem 259: Cantoni G L: The centrality of S-adenosylhomocysteinase in the regulation of the biological utilization of S-adenosylmethionine. In: Biological Met/ivlation and Drug Design:.vperimenta/ and Clinical Roles ofs-adenosv/methionine, edited by Borchardt RT, Creveling CR. Ueland PM, Clifton Ni, Humana Press, 1986, pp Perna AF, Ingrosso D, Galletti P. Zappia V. De Santo NG: Membrane protein damage and methylation reactions in chronic renal failure. Kidney mt SO: , Galletti P. Ingrosso D. Manna C, Clemente G, Zappia V: Protein damage and methylation mediated repair in the erythrocyte. Biochem J 36: , Perna AF, D Aniello A, Lowenson ID, Clarke 5, De Santo NG, Ingrosso D: D-aspartate content of erythrocyte membrane pro- teins is decreased in uremia: implications for the repair of damaged proteins. J Am Soc Nephrol 8: 95-14, Mudd SH, Levy HL. Skovby F: Disorders of transsulfuration. In: The Metabolic Basis ofinherited Disease, edited by Scniver CR, Beaudet AL, Sly WS. Valle D. New York. McGraw Hill, 1989, pp Selhub I, Miller 1W: The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by 5-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Ant J CliiiNutr 55: , Wilcken DL, Dudman NPB, Tyrrell PA, Robertson MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 37: , Arnadottir M, Brattstrom LA, Simonsen, Thysell H, Hultberg B, Andersson A, Nibsson-hle P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. C/in Nephrol 4: Bostom AG, Shemin D, Lapane KL, Hume AL. Yoburn D, Nadeau MR. Bendich A, Selhub J, Rosenberg IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney mt 49: , Macfarlane D: Inhibitors of cyclic nucleotide phosphodiesterases inhibit protein carboxyl methylation in intact blood platelets. J Biol Cheiii 259: , Ubbink JB, Vermaak WJH, Bissbort S: Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 565: , Perna AF. Ingrosso D. De Santo NG, Galletti P, Zappia V: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Jut 47: I Jones BN, Paabo 5, Stein 5: Amino acid analysis and enzymatic sequence determination of peptides by an improved o-phtalabdehyde precolumn labeling procedure. J Liq Chromatogr 4: , Dawson-Saunders B. Trapp RG: Basic and Clinical Biostatistics, Norwalk, CT, Appleton & Lange, I Tsai C, Perrella MA, Yoshizumi M, Hsien C-M, Habe, Schbagel R, Lee M-: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl AcadSci USA 91: , Harpel PC, Chang VT. Bort W: Homocysteine and other sulf-
7 Folates and Hyperhomocysteinemia in Uremia 195 hydryl compounds enhance the binding of lipoprotein(a) to fibrim: A potential biochemical link between thrombosis. atherogenesis. and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89: , Preibisch G, Kuffner C, lstner F: Biochemical model reactions on the prooxidative activity of homocysteine. J Biosci 48: 58-62, Rodgers GM, Kane WH: Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J C/in Invest 77: , Hayashi 1, Honda G. Suzuki K: An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endotheliab cells. Blood 79: , Laidlaw SA, Smolin LA, Davidson WD, Kopple JD: Sulfur amino acids in maintenance hemodialysis patients. Kidney Jut 32: Sl91-S196, Westhuyzen J, Matherson K, Tracey R. Fleming Si: ffect of withdrawal of folic acid supplementation in maintenance hemodialysis patients. C/in Nephrol 4: 96-99, Janssen MJFM, van den Berg M. van Guldener C. Boers GHJ, Stehouwer CDA: Withdrawal of folic acid supplementation in maintenance hemodialysis patients. C/in Nephrol 42: , Toigo G, Situlin R. Vasile A, Guerra UP, Tamaro G, Pagoni G, Sergiani G, Russo M. Guarnieri G: ffects of erythropoietin administration on nutritional state and erythrocyte metabolism in maintenance hemodialysis patients. In: Metabolic and Nutritional Abnormalities in Kidney Disease. Contrib Nephro/ 98: 79-88, 1992
Serum total homocysteine concentration before and after renal transplantation
Kidney International, Vol. 54 (1998), pp. 1380 1384 Serum total homocysteine concentration before and after renal transplantation MARGRET ARNADOTTIR, BJÖRN HULTBERG, JAN WAHLBERG, BENGT FELLSTRÖM, and
More informationEffects of High-Dose Folic Acid and Pyridoxine on Plasma and Erythrocyte Sulfur Amino Acids in Hemodialysis Patients
J Am Soc Nephrol 10: 1287 1296, 1999 Effects of High-Dose Folic Acid and Pyridoxine on Plasma and Erythrocyte Sulfur Amino Acids in Hemodialysis Patients MOHAMED E. SULIMAN,* JOSÉ C. DIVINO FILHO, PETER
More informationSerum Total Homocysteine and Coronary Heart Disease
International Journal of Epidemiology O International Eptctemlotoglcal Association 1995 Vol. 24, No. 4 Printed In Great Britain Serum Total Homocysteine and Coronary Heart Disease EGIL ARNESEN,* HELGA
More informationRandomized Trial of Methylcobalamin and Folate Effects on Homocysteine in Hemodialysis Patients
Original Paper Nephron 2002;91:58 63 Accepted: July 10, 2001 Randomized Trial of Methylcobalamin and Folate Effects on Homocysteine in Hemodialysis Patients Hernán Trimarchi a Amalia Schiel b Emilio Freixas
More informationEffective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy
Kidney International, Vol. 56 (1999), pp. 2292 2296 Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy MALIK TOUAM, JOHANNA ZINGRAFF,
More informationI n the past several years, a large number of invest!-
Homocysteine and Folate Concentrations in Blood from Patients Treated ith Hemodialysi& Tsunenobu Tamura,2 Kelley E. Johnston, and Suzanne M. Bergman 1. Tamura, K.E. Johnston, Department of Nutrition Sciences,
More informationCauses of Hyperhomocysteinemia in Patients With Chronic Kidney Diseases
Causes of Hyperhomocysteinemia in Patients With Chronic Kidney Diseases Giacomo Garibotto, Antonella Sofia, Alessandro Valli, Alice Tarroni, Massimiliano Di Martino, Valeria Cappelli, Francesca Aloisi,
More informationIndependent Risk Factors of Cardiovascular Disease Achieving Healthy Homocysteine Levels
Independent Risk Factors of Cardiovascular Disease Achieving Healthy Homocysteine Levels AUTHORS: JON LEGERE, BRADLEY RALPH, DR. RON LEGERE 15344 N 83RD WAY, SCOTTSDALE, AZ 85260 TEL: 800.528.3144 EMAIL:
More informationPlasma homocysteine concentrations in a Belgian school-age population 1 3
Plasma homocysteine concentrations in a Belgian school-age population 1 3 Corinne De Laet, Jean-Claude Wautrecht, Daniel Brasseur, Michèle Dramaix, Jean-Marie Boeynaems, Jean Decuyper, and André Kahn ABSTRACT
More informationHyperhomocysteinaemia A Risk Factor Worth Considering
REVIEW ARTICLE JIACM 2003; 4(2): 147-51 Hyperhomocysteinaemia A Risk Factor Worth Considering Pramood C Kalikiri* At least nine well-known risk factors are known to play a role in the development of coronary
More informationPlasma total homocysteine and macrovascular complications are associated with food and nutrient intake in patients with Type II diabetes mellitus
Nutrition Research and Practice (2007), 2, 79-83 c2007 The Korean Nutrition Society and the Korean Society of Community Nutrition Plasma total homocysteine and macrovascular complications are associated
More informationHomocysteine is an amino acid produced as an intermediate
CLINICAL REVIEW Homocysteine and Vascular Disease Christopher A. Friedrich, MD, PhD, and Daniel J. Rader, MD Homocysteine is an amino acid produced as an intermediate product in the metabolism of methionine,
More informationBiochemistry: A Short Course
Tymoczko Berg Stryer Biochemistry: A Short Course Second Edition CHAPTER 31 Amino Acid Synthesis 2013 W. H. Freeman and Company Chapter 31 Outline Although the atmosphere is approximately 80% nitrogen,
More informationAmino acid metabolism
Amino acid metabolism The important reaction commonly employed in the breakdown of an amino acid is always the removal of its -amino group. The product ammonia is excreted after conversion to urea or other
More informationEffect of High Dose Folic Acid Therapy on Hyperhomocysteinemia in Hemodialysis Patients: Results of the Vienna Multicenter Study
Effect of High Dose Folic Acid Therapy on Hyperhomocysteinemia in Hemodialysis Patients: Results of the Vienna Multicenter Study J Am Soc Nephrol 11: 1106 1116, 2000 GERE SUNDER-PLASSMANN,* MANUELA FÖDINGER,
More informationEffect of folic acid on methionine and homocysteine metabolism
Kidney International, Vol. (), pp. CLINICAL NEPHROLOGY EPIDEMIOLOGY CLINICAL TRIALS Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease FRANK STAM, COEN VAN GULDENER,
More informationEuropean Journal of Clinical Investigation (2003) 33, VU University Medical Center, Amsterdam, the Netherlands
European Journal of Clinical Investigation (2003) 33, 17 25 Blackwell Science, Ltd S-adenosylhomocysteine and the ratio of S-adenosylmethionine to S-adenosylhomocysteine are not related to folate, cobalamin
More informationHomocysteine Determination in Plasma
omocysteine Determination in Plasma Bruce Peary Solomon, Ph.D. Chester T. Duda, Ph.D. Bioanalytical Systems, Inc. West Lafayette, IN E-mail: bp@bioanalytical.com Recent publications suggest that high homocysteine
More informationHyperhomocysteinaemia in Black patients with cerebral thrombosis
Q J Med 1997; 90:635-639 Hyperhomocysteinaemia in Black patients with cerebral thrombosis R. DELPORT 1, J.B. UBBINK\ W.J.H. VERMAAK 1, H. ROSSOUW 1, P.J. BECKER 2 andj. JOUBERT 3 * From the ^Department
More informationMetabolism of. Sulfur Containing Amino Acids
Metabolism of Sulfur Containing Amino Acids Methionine S CH 3 CH 2 cysteine CH 2 SH CH 2 CHNH 2 COOH CHNH 2 COOH Essential amino acid Non-polar amio acid Glucogenic amino acid Methionine IMPORTANCE: As
More informationREVIEW ARTICLE. Blood Levels of Homocysteine and Increased Risks of Cardiovascular Disease
Blood Levels of Homocysteine and Increased Risks of Cardiovascular Disease Causal or Casual? REVIEW ARTICLE William G. Christen, ScD; Umed A. Ajani, MBBS; Robert J. Glynn, ScD; Charles H. Hennekens, MD
More informationInternational Journal of Current Research in Medical Sciences
International Journal of Current Research in Medical Sciences ISSN: 2454-5716 www.ijcrims.com Coden: IJCRPP(USA) Research Article http://s-o-i.org/1.15/ijcrms-2016-2-1-5 How Raised Homocysteine is Correlated
More informationProspective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease
Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease Lloyd M. Taylor, Jr, MD, Gregory L. Moneta, MD, Gary J. Sexton, PhD,
More informationHomocystinuria: what about mild
Postgrad Med J 1996; 72: 513-518 ( The Fellowship of Postgraduate Medicine, 1996 Classic diseases revisited Summary Hyperhomocysteinaemia is associated with an increased risk of atherosclerotic vascular
More informationCreatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients
Kidney International, Vol. 66 (04), pp. 2422 2428 supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients YOURI E.C. TAES, JORIS R. DELANGHE, DIRK DE BACQUER, MICHEL
More informationHyperhomocysteinemia in Chronic Renal Disease
DISEASE OF THE MONTH J Am Soc Nephrol 10: 891 900, 1999 Hyperhomocysteinemia in Chronic Renal Disease ANDREW G. BOSTOM* and BRUCE F. CULLETON *Memorial Hospital of Rhode Island, Pawtucket, Rhode Island;
More informationHOMOCYSTEINE AND CARDIOVASCULAR DISEASE
Annu. Rev. Medicine 1998. 49:31 62 Copyright 1998 by Annual Reviews Inc. All rights reserved HOMOCYSTEINE AND CARDIOVASCULAR DISEASE H. Refsum, MD and P. M. Ueland, MD Department of Pharmacology, University
More informationHyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
Kidney International, Vol. 52 (1997), pp. 10 20 PERSPECTIVES IN BASIC SCIENCE Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
More informationDoes metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus?
Journal of Internal Medicine 1997; 242: 389 394 Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? E. K. HOOGEVEEN a, P. J. KOSTENSE ac, C. JAKOBS d,
More information9 Metabolic trigger: control of methionine metabolism
9 Metabolic trigger: control of methionine metabolism M.V. Martinov 1,V.M.Vitvitsky 1,E.V.Mosharov 2,R.Banerjee 2,F.I.Ataullakhanov 1 1 National Research Center for Hematology, Moscow, Russia 125167 2
More informationRelationship of Total Homocysteine, Cholesterol, Triglyceride in the Serum and Diastolic Blood Pressure of Patients with Myocardial Infarction
Relationship of Total Homocysteine, Cholesterol, Triglyceride in the Serum and Diastolic Blood Pressure of Patients with Myocardial Infarction Durdi Qujeq *1, Laia Hossini 1 and M. Taghi Salehi Omran 2
More informationPrevalence Of Hyperhomocysteinemia In Patients With Predialysis Chronic Kidney Disease After Folic Acid Food Fortification Of The Canadian Food Supply
Prevalence Of Hyperhomocysteinemia In Patients With Predialysis Chronic Kidney Disease After Folic Acid Food Fortification Of The Canadian Food Supply Pauline B. Darling PhD RD Research Team Research Team
More informationKinetic basis of hyperhomocysteinemia in patients with chronic renal failure
Kidney International, Vol. 52 (1997), pp. 495 52 Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure ANNE B. GUTTORMSEN, PER M. UELAND, EINAR SVARSTAD, and HELGA REFSUM Department
More informationHOMOCYSTEINE METABOLISM
Annu. Rev. Nutr. 1999. 19:217 46 Copyright c 1999 by Annual Reviews. All rights reserved HOMOCYSTEINE METABOLISM J. Selhub Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston,
More informationAMINO ACID METABOLISM
AMINO ACID METABOLISM Synthesis of Urea in Liver The series of reactions that form urea is known as the Urea Cycle or the Krebs-Henseleit Cycle. The urea cycle operates only to eliminate excess nitrogen.
More informationPredictors of Change in Plasma Total Cysteine: Longitudinal Findings from the Hordaland Homocysteine Study
Clinical Chemistry 49:1 113 120 (2003) Lipids, Lipoproteins, and Cardiovascular Risk Factors Predictors of Change in Plasma Total Cysteine: Longitudinal Findings from the Hordaland Homocysteine Study Lina
More informationThe Effect of a Subnormal Vitamin B-6 Status on Homocysteine Metabolism
The Effect of a Subnormal Vitamin B-6 Status on Homocysteine Metabolism Johan B. Ubbink,* Annatjie van der Merwe,* Rhena Delport,* Robert H. Allen, Sally P. Stabler, Reiner Riezler, and Vermaak* *Department
More informationPrevalence of Hyperhomocysteinemia in Patients with Predialysis Chronic Kidney Disease after Folic Acid Food Fortification of the Canadian Food Supply
Prevalence of Hyperhomocysteinemia in Patients with Predialysis Chronic Kidney Disease after Folic Acid Food Fortification of the Canadian Food Supply by Linda Jane Paterson A thesis submitted in conformity
More informationSally P. Stabler * and Robert H. Allen. Metabolism. Clinical Chemistry 50: (2004) Endocrinology and
Clinical Chemistry 50:2 365 372 (2004) Endocrinology and Metabolism Quantification of Serum and Urinary S-Adenosylmethionine and S-Adenosylhomocysteine by Stable-Isotope- Dilution Liquid Chromatography
More informationInsulin Resistance Is Not Related to Plasma Homocysteine Concentration in Healthy Premenopausal Women
Physiol. Res. 55: 285-29, 26 Insulin Resistance Is Not Related to Plasma Homocysteine Concentration in Healthy Premenopausal Women F. TANRIKULU-KILIÇ, S. BEKPINAR, Y. ÜNLÜÇERÇI, Y. ORHAN 1 Department of
More informationNitrous Oxide Induced Elevation Of Plasma Homocysteine And Methylmalonic Acid Levels And Their Clinical Implications
ISPUB.COM The Internet Journal of Anesthesiology Volume 8 Number 2 Nitrous Oxide Induced Elevation Of Plasma Homocysteine And Methylmalonic Acid Levels And Their Clinical Implications P Kalikiri, R Sachan
More informationHyperhomocysteinaemia and premature coronary artery disease in the Chinese
Heart 1996;76:117-122 Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong Y I Lolin S K Cheng C F Chan C P Pang J R L Masarei Department of Medicine,
More informationMETHYLENETETRAHYDROFOLATE REDUCTASE GENE AMONG THE JAPANESE
Jpn J Human Genet 41, 247 251, 1996 Short Communication A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE GENE AMONG THE JAPANESE POPULATION Hisahide NISHIO, L* Myeong Jin LEE, ~ Motoko FuJlI, 1
More informationHomocysteine (Hcy) is a non-essential, thiol containing, amino acid. It is
Abstract Homocysteine (Hcy) is a non-essential, thiol containing, amino acid. It is produced in the body as an intermediate during the break down of methionine. Hcy has been associated with several diseases
More informationAmino acids. Ing. Petrová Jaroslava. Workshop on Official Controls of Feed AGR 46230, , Ankara. Turkey ÚKZÚZ - NRL RO Praha 1
Amino acids Ing. Petrová Jaroslava Workshop on Official Controls of Feed AGR 46230, 6. 7. 12. 2011, Ankara. Turkey 6.12.2011 ÚKZÚZ - NRL RO Praha 1 Content of this presentation 1. Function of amino acids
More informationRole of homocysteine, cystathionine and methylmalonic acid measurement for diagnosis of vitamin deficiency in high-aged subjects
European Journal of Clinical Investigation (2000) 30, 1083±1089 Role of homocysteine, cystathionine and methylmalonic acid measurement for diagnosis of vitamin deficiency in high-aged subjects W. Herrmann
More informationMulticenter Analytical Evaluation of an Automated Immunoassay for Total Plasma Homocysteine
Annals o f Clinical & Laboratory Science, vol. 30, no. 2, 2000 185 Multicenter Analytical Evaluation of an Automated Immunoassay for Total Plasma Homocysteine Alan H.B. W u,1 Verena H oltm an,1 Fred S.
More informationHOMOCYSTEINE (H(e)) is a nonprotein-forming, thiolcontaining
0163-769X/99/$03.00/0 Endocrine Reviews 20(5): 738 759 Copyright 1999 by The Endocrine Society Printed in U.S.A. Hyperhomocysteinemia and the Endocrine System: Implications for Atherosclerosis and Thrombosis
More informationEVERYDAY CLINICAL APPLICATION OF TELOMERE AND AGING SUPPORT PRESENTED BY: Fred Pescatore, MD, MPH, CCN
EVERYDAY CLINICAL APPLICATION OF TELOMERE AND AGING SUPPORT PRESENTED BY: Fred Pescatore, MD, MPH, CCN Financial Disclosure: Consultant to DaVinci Labs AGENDA Overview of the following: Methylation Telomere
More informationDetermination of Total Homocysteine in Human Plasma by Isocratic High-Performance Liquid Chromatography
Eur J Clin Chem Clin Biochem 1997; 35(9):687-691 1997 by Walter de Gruyter Berlin New York Determination of Total Homocysteine in Human Plasma by Isocratic High-Performance Liquid Chromatography Andrea
More informationImpairment of homocysteine metabolism in patients with retinal vascular occlusion and non-arteritic ischemic optic neuropathy
Clin Chem Lab Med 2005;43(10):1020 1025 2005 by Walter de Gruyter Berlin New York. DOI 10.1515/CCLM.2005.179 2005/230 Impairment of homocysteine metabolism in patients with retinal vascular occlusion and
More informationFolic acid treatment increases homocysteine remethylation and methionine transmethylation in healthy subjects
Clinical Science (2005) 108, 449 456 (Printed in Great Britain) 449 Folic acid treatment increases homocysteine remethylation and methionine transmethylation in healthy subjects Frank STAM, Yvo M. SMULDERS,
More informationHomocysteine is a thiol-containing amino acid derived
Plasma Homocysteine Concentrations in the Acute and Convalescent Periods of Atherothrombotic Stroke D.J. Meiklejohn, MBChB; M.A. Vickers, MD; R. Dijkhuisen, MD; M. Greaves, PhD Background and Purpose Homocysteine
More informationClinical Policy: Homocysteine Testing Reference Number: CP.MP.121
Clinical Policy: Reference Number: CP.MP.121 Effective Date: 08/16 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationProtein-bound Homocyst(e)ine A Possible Risk Factor for Coronary Artery Disease
Protein-bound Homocyst(e)ine A Possible Risk Factor for Coronary Artery Disease Soo-Sang Kang, Paul W. K. Wong, Heron Y. Cook, Marija Norusis, and Joseph V. Messer Departments ofpediatrics, Preventive
More information!!"#$%&'#()*+,-).(&"/+0&'12'
LAB #: Sample Report PATIENT: Sample Patient ID: SEX: Female DOB: 01/01/1985 AGE: 33 CLIENT #: 12345 DOCTOR: Sample Doctor Doctors Data Inc 3755 Illinois Ave St. Charles, IL 60174 U.S.A.!!"#$%&'#()*+,-).(&"/+0&'12'
More informationPlasma Protein Aspartyl Damage Is Increased in Hemodialysis Patients: Studies on Causes and Consequences
J Am Soc Nephrol 15: 2747 2754, 2004 Plasma Protein Aspartyl Damage Is Increased in Hemodialysis Patients: Studies on Causes and Consequences ALESSANDRA F. PERNA,* DIEGO INGROSSO, ERSILIA SATTA,* CINZIA
More informationElevated serum homocysteine level has a positive correlation with serum cardiac troponin I in patients with acute myocardial infarction
Bangladesh Med Res Counc Bull 2012; 38: 9-13 Elevated serum homocysteine level has a positive correlation with serum cardiac troponin I in patients with acute myocardial infarction Abstract Alam N, Khan
More informationThe New England Journal of Medicine PLASMA HOMOCYSTEINE LEVELS AND MORTALITY IN PATIENTS WITH CORONARY ARTERY DISEASE
PLASMA HOMOCYSTEINE LEVELS AND MORTALITY IN PATIENTS WITH CORONARY ARTERY DISEASE OTTAR NYGÅRD, M.D., JAN ERIK NORDREHAUG, M.D., HELGA REFSUM, M.D., PER MAGNE UELAND, M.D., MIKAEL FARSTAD, M.D., AND STEIN
More informationPlasma Homocysteine Concentrations in a Healthy Population Living in Burkina Faso
CURRENT THERAPEUTIC RESEARCH@ VOL 61, No 9, SEPTEMBER 2000 Plasma Homocysteine Concentrations in a Healthy Population Living in Burkina Faso Jacques Simpork, Salvatore Pignatelli, Sergio Barlati,* Mariano
More informationDeterminants and Vitamin Responsiveness of Intermediate Hyperhomocysteinemia ( 40 mol/liter)
Determinants and Vitamin Responsiveness of Intermediate Hyperhomocysteinemia ( 40 mol/liter) The Hordaland Homocysteine Study Anne Berit Guttormsen,* Per Magne Ueland,* Ingerid Nesthus, Ottar Nygård, Jörn
More informationand Folic Acid in Type II Diabetes Mellitus Patients.
Research Article ISSN: 974-6943 M. Prabhuet al. / Journal of Pharmacy Research 214,8(1),1398-145 Available online through http://jprsolutions.info Investigation of the Effect of on the Level of Plasma
More informationCBS Deficient Homocystinuria.
CBS Deficient Homocystinuria. Kenneth N. Maclean PhD University of Colorado School of Medicine Department of Pediatrics The methionine cycle Alternative metabolic fates for Hcy Extrusion into the extracellular
More informationChapter 2 An Overview of Homocysteine Metabolism
Chapter 2 An Overview of Homocysteine Metabolism Mammals, in contrast to bacteria and plants, cannot make their own methionine (Met). Thus, in humans and animals, Met is an essential amino acid that is
More informationHYPERHOMOCYSTEINEMIA: RELATION TO CARDIOVASCULAR DISEASE (PDF) HOMOCYSTEINE AND RELATED B-VITAMIN STATUS IN COELIAC
PDF HYPERHOMOCYSTEINEMIA: RELATION TO CARDIOVASCULAR DISEASE (PDF) HOMOCYSTEINE AND RELATED B-VITAMIN STATUS IN COELIAC 1 / 5 2 / 5 3 / 5 homocysteine related vitamins pdf Hyperhomocysteinemia: Relation
More informationHomocysteine and ischaemic stroke in men: the Caerphilly study
J Epidemiol Community Health 2001;55:91 96 91 Homocysteine and ischaemic stroke in men: the Caerphilly study U B Fallon, P Elwood, Y Ben-Shlomo, J B Ubbink, R Greenwood, G Davey Smith Department of Social
More informationSerum Homocysteine Levels in Various Stages of Chronic Kidney Disease
Original Research Article Serum Homocysteine Levels in Various Stages of Chronic Kidney Disease Kalpana S. Mehta 1*, Sandip P. Bhurke 2, Suyash V. Sharma 3 1*Professor & Head, 2 Associate Professor, 3
More informationHyperhomocysteinemia is known to be an. Methylenetetrahydrofolate Reductase Gene Polymorphism. Relation to Blood Pressure and Cerebrovascular Disease
AJH 1998;11:1019 1023 BRIEF COMMUNICATIONS Methylenetetrahydrofolate Reductase Gene Polymorphism Relation to Blood Pressure and Cerebrovascular Disease Yukiko Nakata, Tomohiro Katsuya, Seiju Takami, Noriyuki
More informationImpaired Homocysteine Metabolism and Atherothrombotic Disease. Philippe Durand, Michel Prost, Nadine Loreau, Suzanne Lussier-Cacan, and Denis Blache
0023-6837/01/8105-645$03.00/0 LABORATORY INVESTIGATION Vol. 81, No. 5, p. 645, 2001 Copyright 2001 by The United States and Canadian Academy of Pathology, Inc. Printed in U.S.A. MINIREVIEW Impaired Homocysteine
More informationFunctional Blood Chemistry & CBC Analysis
Functional Blood Chemistry & CBC Analysis Session 10 Inflammation Markers The 19 Deadly Sins of Heart Disease 1. Excess LDL 2. Excess Total cholesterol 3. Low HDL 4. Excess Triglycerides 5. Oxidized LDL
More informationThe Effect of Glutathione Modulation on the Concentration of Homocysteine in Plasma of Rats
C Pharmacology & Toxicology 2000, 87, 103 107. Printed in Denmark. All rights reserved Copyright C ISSN 0901-9928 The Effect of Glutathione Modulation on the Concentration of Homocysteine in Plasma of
More informationAssociation of B vitamins status and homocysteine levels in elderly Taiwanese
Asia Pac J Clin Nutr 2005; 14 (3):250-255 250 Original Article Association of B vitamins status and homocysteine levels in elderly Taiwanese Kuan-Ju Chen MS, 1,2 Wen-Harn Pan PhD, 1 Feili-Lo Yang PhD,
More informationAsubstantial body of evidence from observational epidemiological
Effect of Dietary Patterns on Serum Homocysteine Results of a Randomized, Controlled Feeding Study Lawrence J. Appel, MD, MPH; Edgar R. Miller III, MD, PhD; Sun Ha Jee, PhD; Rachael Stolzenberg-Solomon,
More informationImpact of Serum Homocysteine on Platelet Count in Stable Hemodialysis Patients
Impact of Serum Homocysteine on Platelet Count in Stable Hemodialysis Patients Hamid Nasri, MD Hemodialysis Section, Hajar Medical, Educational and Therapeutic Center, Shahrekord University of Medical
More informationNITROGEN METABOLISM An Overview
1 University of Papua New Guinea School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PBL Seminar & Health Sciences NITROGEN METABOLISM
More informationMethylation demand: a key determinant of homocysteine metabolism
Vol. 51 No. 2/2004 405 413 QUARTERLY Review Methylation demand: a key determinant of homocysteine metabolism John T. Brosnan 1, Rene L. Jacobs 2, Lori M. Stead 1 and Margaret E. Brosnan 1 1 Department
More informationKey words: Risk factor. Hyperhomocysteinemia. Ischemic heart disease. Smoking.
j c p s p September 2004 Volume 14 Number 09 September 2004 Home JCPSP Home Sep JCPSP Contents Email JCPSP HYPERHOMOCYSTEINEMIA AS A RISK FACTOR FOR ISCHEMIC HEART DISEASE Muhammad Aamir, Abdus Sattar,*
More informationImportance of Elevated Plasma Homocysteine Levels as a Risk Factor for Atherosclerosis
Importance of Elevated Plasma Homocysteine Levels as a Risk Factor for Atherosclerosis Philippe A. Masser, MD, Lloyd M. Taylor, Jr, MD, and John M. Porter, MD Division of Vascular Surgery, Oregon Health
More informationFolate and Vitamin B 6 From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women
Original Contributions Folate and Vitamin B 6 From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women Eric B. Rimm, ScD; Walter C. Willett, MD, DrPH; Frank B. Hu, MD, PhD; Laura
More informationPrevalence of malnutrition in dialysis
ESPEN Congress Cannes 2003 Organised by the Israel Society for Clinical Nutrition Education and Clinical Practice Programme Session: Nutrition and the Kidney Malnutrition and Haemodialysis Doctor Noël
More informationGeneral introduction
1 General introduction Essentials of homocysteine and 1-carbon metabolism Cardiovascular disease (CVD) is one of the most prominent causes of death in the modern world. Research has shown that a combination
More informationNitrous Oxide induced Elevation of Plasma Homocysteine and Methylmalonic Acid Levels and their Clinical Implications
SHORT COMMUNICATION JIACM 2005; 6(1): 48-52 Abstract Nitrous Oxide induced Elevation of Plasma Homocysteine and Methylmalonic Acid Levels and their Clinical Implications Pramood C Kalikiri*, Reena G Sachan*
More informationEpidemiological evidence indicates that a raised plasma
Does Folic Acid Decrease Plasma Homocysteine and Improve Endothelial Function in Patients With Predialysis Renal Failure? J. Thambyrajah, MRCP; M.J. Landray, MRCP; F.J. McGlynn, RGN; H.J. Jones, RGN, BSc;
More informationReview Article. Mechanisms of Disease
Review Article Mechanisms of Disease F RANKLIN H. EPSTEIN, M.D., Editor HMCYSTEINE AND ATHERTHRMBSIS GERGE N. WELCH, M.D., AND JSEPH LSCALZ, M.D., PH.D. IN 1969, McCully made the clinical observation linking
More informationDevelopment of Methyltransferase Activities of Human Fetal Tissues
Pediat. Res. 7: 527-533 (1973) Brain folate cystathionase homocyst(e)ine cyst(e)ine methyltransferase fetus serine Development of Methyltransferase Activities of Human Fetal Tissues GERALD E. GAULIJ 301,
More informationVitamin B 12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products
Research Recherche Vitamin B 12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products Julie Robertson, Francesco Iemolo, Sally P. Stabler, Robert H.
More informationnumber Done by Corrected by Doctor Dr.Diala
number 32 Done by Mousa Salah Corrected by Bahaa Najjar Doctor Dr.Diala 1 P a g e In the last lecture we talked about the common processes between all amino acids which are: transamination, deamination,
More informationLowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials
minute. Airway hypoxia was discontinued as soon as possible in each infant who showed this degree of desaturation; it should be remembered that this required the tent to be opened and the gas mixture to
More informationAbundant evidence has accumulated supporting the association
Folate, Vitamin B 6, and B 12 Intakes in Relation to Risk of Stroke Among Men Ka He, MD; Anwar Merchant, DMD; Eric B. Rimm, ScD; Bernard A. Rosner, PhD; Meir J. Stampfer, MD; Walter C. Willett, MD; Alberto
More informationScope of the talk. Riboflavin, other dairy B vitamins and cardiovascular health. Epidemiology of milk consumption and CVD
Riboflavin, other dairy B vitamins and cardiovascular health Professor Hilary J Powers University of Sheffield United Kingdom Scope of the talk Importance of dairy products to B vitamin intakes Epidemiological
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationHyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12
Nephrol Dial Transplant (2002) 17: 455 461 Original Article Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12
More informationMidterm 2. Low: 14 Mean: 61.3 High: 98. Standard Deviation: 17.7
Midterm 2 Low: 14 Mean: 61.3 High: 98 Standard Deviation: 17.7 Lecture 17 Amino Acid Metabolism Review of Urea Cycle N and S assimilation Last cofactors: THF and SAM Synthesis of few amino acids Dietary
More informationThe Role of Homocysteine in Human Health
K.J. McLaughlin, B.P.E., B.Sc., D.C., MA.Sc., R.N.C. 1 Introduction For the last two decades, the Modus Operandi of most health care providers managing their patients with atherosclerosis was to prescribe
More informationInfluence of folic acid on plasma homocysteine levels & arterial endothelial function in patients with unstable angina
Indian J Med Res 129, March 2009, pp 279-284 Influence of folic acid on plasma homocysteine levels & arterial endothelial function in patients with unstable angina Hangyuan Guo, Jufang Chi, Yangbo Xing
More informationStudent Number: To form the polar phase when adsorption chromatography was used.
Name: Student Number: April 14, 2001, 1:30 AM - 4:30 PM Page 1 (of 4) Biochemistry II Lab Section Final Examination Examiner: Dr. A. Scoot 1. Answer ALL questions in the space provided.. 2. The last page
More informationB vitamin status and inflammatory markers
Atherosclerosis 169 (2003) 169/174 www.elsevier.com/locate/atherosclerosis B vitamin status and inflammatory markers Aaron R. Folsom a, *, Moïse Desvarieux a,f. Javier Nieto b, Lori L. Boland a, Christie
More informationThe effect of nickel on homocysteine metabolism in patients with end-stage renal disease on hemodialysis and in vitro in peripheral mononuclear cells
SHORT THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (PHD) The effect of nickel on homocysteine metabolism in patients with end-stage renal disease on hemodialysis and in vitro in peripheral mononuclear
More informationStudent Number: THE UNIVERSITY OF MANITOBA April 10, 2000, 9:00 AM - 12:00 PM Page 1 (of 4) Biochemistry II Lab Section Final Examination
Name: Student Number: THE UNIVERSITY OF MANITOBA April 10, 2000, 9:00 AM - 12:00 PM Page 1 (of 4) Biochemistry II Lab Section Final Examination Examiner: Dr. A. Scoot 1. Answer ALL questions.. 2. Questions
More informationRoles of homocysteine in cell metabolism
Eur. J. Biochem. 268, 3871±3882 (2001) q FEBS 2001 REVIEW ARTICLE Roles of homocysteine in cell metabolism Old and new functions Miguel AÂ. Medina, Jose L. Urdiales and MarõÂa I. Amores-Sa nchez Departamento
More information